583 related articles for article (PubMed ID: 27111903)
1. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
2. The science of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
[No Abstract] [Full Text] [Related]
3. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812
[No Abstract] [Full Text] [Related]
6. Immune Checkpoint Therapy in Melanoma.
Callahan MK
Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
8. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
9. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
10. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
Campbell MT; Siefker-Radtke AO; Gao J
Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
Ring KL; Pakish J; Jazaeri AA
Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Therapies in Prostate Cancer.
Goswami S; Aparicio A; Subudhi SK
Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Therapy in Head and Neck Cancers.
Msaouel P; Massarelli E
Cancer J; 2016; 22(2):108-16. PubMed ID: 27111906
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
Cui S
Med Sci Monit; 2017 Jul; 23():3360-3366. PubMed ID: 28697172
[TBL] [Abstract][Full Text] [Related]
16. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
17. Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Gao X; McDermott DF
Cancer J; 2018; 24(4):171-179. PubMed ID: 30119080
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitors in breast cancer: hype or promise?
McArthur HL
Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
[No Abstract] [Full Text] [Related]
20. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
